Literature DB >> 21091671

The role of drugs in the induction and/or exacerbation of psoriasis.

Kabbur Hanumanthappa Basavaraj1, Navya Mysore Ashok, Ramesh Rashmi, Thaggikuppe Krishnamurthy Praveen.   

Abstract

Psoriasis is a common skin disorder; knowledge of the factors that may induce, trigger, or exacerbate the disease is of primary importance in clinical practice. Drug intake is a major concern in this respect, as new drugs are constantly being added to the list of factors that may influence the course of this disease. Drug ingestion may result in exacerbation of pre-existing psoriasis, in induction of psoriatic lesions on clinically uninvolved skin in patients with psoriasis, or in precipitation of the disease in persons without family history of psoriasis or in predisposed individuals. In view of their relationship to drug-provoked psoriasis, therapeutic agents may be classified as drugs with strong evidence for a causal relationship to psoriasis, drugs about which there are considerable but insufficient data to support the induction or aggravation of the disease, and drugs that are occasionally reported to be associated with aggravation or induction. This review focuses on the most common causative agents for drug-induced, drug-triggered, or drug-aggravated psoriasis, such as β-blockers, lithium, synthetic antimalarial drugs, nonsteroidal anti-inflammatory agents, and tetracyclines, and the mechanisms of action of these drugs in the pathogenesis of psoriasis.
© 2010 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21091671     DOI: 10.1111/j.1365-4632.2010.04570.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  29 in total

1.  A case of generalized ostraceous psoriasis mimicking dermatitis neglecta.

Authors:  Bianca Angelina Macêdo do Nascimento; Alessandra Haber Carvalho; Carolina Moraes Dias; Thaiane Lima Lage; Clívia Maria Oliveira Carneiro; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

2.  Norepinephrine and adenosine-5'-triphosphate synergize in inducing IL-6 production by human dermal microvascular endothelial cells.

Authors:  Lori L Stohl; Julie B Zang; Wanhong Ding; Michela Manni; Xi K Zhou; Richard D Granstein
Journal:  Cytokine       Date:  2013-09-08       Impact factor: 3.861

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].

Authors:  U Kiltz; J Sieper; H Kellner; D Krause; M Rudwaleit; J-F Chenot; A Stallmach; S Jaresch; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

4.  Genetic Epidemiology of Psoriasis.

Authors:  Rashmi Gupta; Maya G Debbaneh; Wilson Liao
Journal:  Curr Dermatol Rep       Date:  2014-03

Review 5.  The role of xenobiotics in triggering psoriasis.

Authors:  Jasna Grželj; Marija Sollner Dolenc
Journal:  Arch Toxicol       Date:  2020-08-24       Impact factor: 5.153

Review 6.  [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions].

Authors:  P Mayser
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

7.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

8.  Inflammatory versus Anti-inflammatory Profiles in Major Depressive Disorders-The Role of IL-17, IL-21, IL-23, IL-35 and Foxp3.

Authors:  Małgorzata Gałecka; Katarzyna Bliźniewska-Kowalska; Agata Orzechowska; Janusz Szemraj; Michael Maes; Michael Berk; Kuan-Pin Su; Piotr Gałecki
Journal:  J Pers Med       Date:  2021-01-23

Review 9.  Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs.

Authors:  Ana M Martins; Andreia Ascenso; Helena Margarida Ribeiro; Joana Marto
Journal:  Mol Neurobiol       Date:  2020-02-15       Impact factor: 5.590

10.  Association of Benzodiazepine Receptor Agonist Use With Changes in Psoriasis Severity in Adult Population: A Population-Based Study.

Authors:  Ke-Ting Pan; I-Hsun Li; Hui-Han Kao; Yi-Hsien Chen; Pei-Xun Zhong; Li-Ting Kao
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.